Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placeboTreatment effect was consistent with or without background therapy and BMS-986278 was well tolerated, with rates of adverse...

Related Keywords

Italy ,United States ,Milan ,Lombardia ,American ,Bristol Myers Squibb ,Tameraj Corte ,Jonathan Sadeh ,Department Of Respiratory Medicine ,American Thoracic Society ,Immunology Development ,Instagram ,European Respiratory Society ,International Congress ,Exchange Commission ,Linkedin ,Twitter ,Youtube ,Facebook ,Abstracts Leading ,Respiratory Medicine Trials ,Professor Tamera ,Consultant Respiratory Physician ,Interstitial Lung Disease ,Respiratory Medicine ,Royal Prince Alfred Hospital ,Bristol Myers ,International Conference ,Fibrosis Trial ,Myers Squibb ,Pioneering Paths Forward ,Transform Patient ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,